SUMMARYLung cancer is one of the leading causes of cancer mortality and overall treatment outcomes for lung cancer are still to be considered disappointing despite of development of new medical therapeutics on cancer. Cytostatic agents are considered as novel medication in the treatment of cancer though its benefit is most appropriately assessed through survival end points rather than the objective-response end points. We present a case of a lung adenocarcinoma patient who showed tumor lesion in patient's two different lung sites. From the day of diagnosis, the tumor lesion stayed with the almost same size with more than 1 year of Allergen-Removed Rhus Verniciflua Stokes (A-RVS) based Traditional Korean Medicine treatment without any western conventional treatment. No significant side effect was noted and the patient maintained good performance status throughout the treatment period. We assume A-RVS may have cytostatic effect on NSCLC patient and our observation justifies further investigation.

No abstract